Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its CEO, Lisa Ricciardi, will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference in San Francisco on October 6-7, 2022. Cognition will be featured in a panel discussion titled ‘Wave of Innovation for Alzheimer’s Disease’ on October 7, 2022, from 9:00 a.m. to 10:00 a.m. PT. The presentation will be exclusive to conference attendees, with no webcast available. Cognition focuses on developing small molecule therapeutics for age-related neurodegenerative diseases, including clinical trials for CT1812 targeting Alzheimer’s and dry AMD.
Cognition Therapeutics has received a $2.14 million grant from the National Institute on Aging to support the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease. This trial aims to assess the impact of CT1812 on EEG patterns linked to memory function. The funding will help advance the study, which has faced delays due to the pandemic. The SEQUEL study involves 16 participants randomized to receive CT1812 or a placebo for 28 days, followed by a crossover period. Previous funding included a $3.2 million grant in 2020.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced management's participation in two September 2022 investment conferences. The H.C. Wainwright 24th Annual Global Investment Conference will occur on September 14, 2022, in New York City, featuring a presentation from 10:30am to 11:00am ET. The Ladenburg Thalmann Healthcare Conference will follow on September 29, 2022, with a presentation from 1:30pm to 1:55pm ET. Live webcasts will be available on the company’s investor website.
Cognition focuses on developing therapeutics for age-related diseases, notably investigating its lead candidate CT1812 for Alzheimer's and related conditions.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) reported optimistic advancements in its clinical trials during Q2 2022, including the initiation of patient dosing in the SHIMMER study for dementia with Lewy bodies and the SHINE study for mild-to-moderate Alzheimer's disease. The company presented promising preclinical data for its dry age-related macular degeneration (dry AMD) program. Financially, CGTX recorded a net loss of $5.8 million for Q2 2022, increasing from $2.8 million in Q2 2021. As of June 30, 2022, the company held $45.8 million in cash and expects to maintain funding into Q4 2023.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) presented insightful findings at the Alzheimer’s Association International Conference on August 4, 2022. Results from the SPARC study highlighted the effects of CT1812 on crucial Alzheimer’s biomarkers, particularly showing a decrease in YKL-40, an inflammation marker, in patients, suggesting a potential therapeutic benefit. Additionally, CT1812 impacted clusterin levels, associated with genetic risks for Alzheimer’s. The company remains optimistic as it proceeds with the ongoing Phase 2 SHINE study.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) will release its second-quarter financial results for the period ending June 30, 2022, on August 9, 2022, before market opening. The company focuses on developing small molecule therapeutics for age-related central nervous system and retinal disorders. Its lead candidate, CT1812, is in clinical trials for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. This announcement highlights the company's ongoing commitment to addressing serious health issues related to aging.
Cognition Therapeutics (NASDAQ: CGTX) announces its participation in the 2022 Alzheimer’s Association International Conference (AAIC) from July 31 to August 4. The company will present new proteomic analyses from the SPARC clinical study, showcasing the impact of CT1812 on Alzheimer’s disease biomarkers. CT1812, an oral small molecule targeting sigma-2 receptors, shows potential therapeutic benefits. Cognition is conducting multiple clinical studies, with results from SHINE and SEQUEL expected in early 2023. The company has secured over $168 million in grant funding.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has initiated its Phase 2 SHIMMER clinical trial for CT1812, targeting dementia with Lewy bodies (DLB). The trial, supported by a $30 million NIA grant, aims to enroll 120 adults aged 50-80 with DLB. CT1812 is an oral therapeutic intended to address DLB's underlying biology, which currently lacks disease-modifying treatments. Primary investigator Dr. James E. Galvin emphasized the trial's importance in exploring a unique mechanism of action against this severe condition.
Cognition Therapeutics (Nasdaq: CGTX) will present at the JMP Securities Life Sciences Conference on June 16, 2022. CEO Lisa Ricciardi will provide an update on the development of small-molecule therapeutics for age-related degenerative diseases. The presentation will focus on their lead candidate, CT1812, which is being studied in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. A live and archived webcast will be available online.
Cognition Therapeutics (Nasdaq: CGTX) will host a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET, focusing on dry age-related macular degeneration (dry AMD). The company plans to initiate a Phase 2 study with its lead candidate, CT1812, in the second half of 2022. Notable speakers include Dr. Mary Hamby and Dr. Karl Csaky, who will discuss recent findings and the current treatment landscape for dry AMD. The event is free to register and will also offer a live Q&A session.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
